Lymphomas are a group of haematological malignancies that are amongst the top ten cancers worldwide. Broadly, they may be divided into Hodgkin lymphomas and non-Hodgkin lymphomas of B-cell or T/NK-cell immunophenotypic subtypes. In terms of therapeutics, patients commonly receive multi-agent chemoimmunotherapy in the frontline setting. In the relapsed setting, haematopoetic stem cell transplant and CAR-T therapy remain the only potentially-curative options for eligible patients, with other agents such as targeted small molecule inhibitors, immune checkpoint inhibitors, and novel drugs providing additional options for disease control. Recently, advances in “omic” technologies have provided the opportunity to stratify lymphomas into distinct molecular subtypes, contributing to an improved understanding of disease pathobiology. However, the clinical implications of these findings often remain unclear at this juncture.
This Topical Collection aims to collect papers dealing with the latest discoveries in lymphoma, particularly those that impact on clinical management and therapeutics. We welcome both original articles on clinical and translational research on lymphomas, as well as review articles that integrate knowledge in the field.
Keywords: Lymphoma; Hematology; Therapeutics; Blood; Genomics